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PERSPECTIVES IN CLINICAL NEPHROLOGY
IgA nephropathy
Since immunoglobulin A nephropathy (IgAN) was first de-
scribed in the seminal papers by Berger [1, 2], we have learned
much descriptively about its epidemiology, associations, natural
history, and pathology, but the pathogenetic mechanisms remain
largely uncertain. Although the histopathologic criterion for
IgAN—the dominance or codominance of IgA deposition in the
mesangium—suggests a single entity, it may as well characterize a
group of diseases or "IgA-associated nephropathies," a concept
that better suits this discussion. From the outset [2], Henoch-
Schönlein purpura (HSP), clearly a systemic illness, has been
closely linked to IgAN, which is defined by the absence of systemic
features. Indeed, in some studies investigators include HSP as
part of the spectrum of IgAN. This view is justified by several
linkages between these two disease entities. Other considerations
in the spectrum of glomerulopathies characterized by IgA depo-
sition, such as nephritis associated with systemic lupus erythema-
tosus (SLE) and hepatic glomerulosclerosis, are clinically distinct
and will be mentioned only as they relate to the differential
diagnosis.
The IgA system
The primary function of the IgA system is to prevent the
invasion of the internal milieu by a vast array of microbial, food,
and environmental antigens [3]. Familiarity with some basic
features of IgA biology provides a helpful foundation for under-
standing the significance of some clinical and pathogenetic obser-
vations: More IgA is produced daily—about 66 mg/kg body
weight—than all other immunoglobulin isotypes combined [4].
Two distinctive systems produce IgA: the systemic compartment,
which includes the bone marrow, lymph nodes, tonsils, and spleen;
and the mucosal or secretory system, which includes the gut,
salivary glands, respiratory tract, and breast. These systems ap-
pear to function for the most part independently of each other [5].
In humans, two isotype subclasses, IgAl and IgA2, are recognized
along with two allotypes of the IgA2 subclass, A2m(1) and
A2m(2). Since the A2m(1) allotype, unlike A2m(2), is not con-
nected by interchain disulfide bonds, it is more readily cleaved by
IgA bacterial proteases [6]. IgA2 is produced predominately in the
mucosal compartment; its production in the systemic compart-
ment is less than 10% of the total. In the systemic compartment,
monomers predominate whereas multimers do in the secretory
compartment. Multimeric IgA—as well as 1gM—contains J-chain,
a component that is linked to the heavy chain in the formation of
multimers. Multimeric IgA also acquires secretory component at
the basolateral membrane of epithelial cells; secretory component
is necessary for the secretion of IgA across the mucosa [7].
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Epidemiology
IgAN is considered the most common glomerular disease
worldwide [8]; its prevalence varies considerably among and
within countries. In the western Pacific rim, particularly Japan,
prevalences approaching 50% of all glomerular diseases have
been observed [9] whereas in Europe, lower prevalences of 10 to
30% have been reported [10]. In the United States, while rates as
low as 2% have been reported in some areas [10], American
Indians in the Southwest have a remarkable prevalence of over
35% [11]. As emphasized by several authors [12, 13], it is now
generally recognized that the local indications for kidney biopsy as
well as health screening practices will profoundly influence these
statistics. For example, in Great Britain, where early studies
reported rates of less than 5% [14], a more recent careful analysis
of kidney biopsies in Scotland showed that 37% of patients who
had a biopsy for the diagnosis of asymptomatic hematuria had
IgAN [15]. In addition, the prevalence of other diseases charac-
terized by IgA mesangial deposition, particularly liver diseases,
must be carefully excluded when a restricted group shows a high
prevalence of apparent IgAN.
Gender and race are important factors in the epidemiology.
Virtually all studies show a male predominance of at least 2:1 [12].
Unlike the high frequency of most other glomerular diseases in
blacks, both IgAN and HSP are uncommon in blacks whether in
the United States or in Africa [16, 17]. This finding is not related
to the frequency of kidney biopsies among races. This low
prevalence of IgAN in blacks has been postulated to be related to
a structural property of IgA2, since the frequency of the A2m(1)
allotype is 0.98 in whites but only 0.36 in blacks [18]. Because the
A2m(2) allotype is resistant to cleavage unlike A2m(1), homozy-
gosity for the A2m(2) allele in blacks was predicted to be
protective against IgAN [19]. This hypothesis would predict that
blacks with IgAN should have the A2m(1) allotype, which pre-
dominates in whites. However, in a study of 18 black patients with
IgAN, only three were homozygous for A2m(1) while four were
homozygous for A2m(2) and 11 were heterozygous [20]; the
clinical course did not appear to differ among these three groups.
The clinical course in blacks with IgAN also does not differ
significantly from that in whites [21]. Thus, this structural differ-
ence between the two allotypes and the lower frequency of the
A2m(1) allotype in blacks does not account for their low preva-
lence of IgAN.
Familial and regional clustering of IgAN has also been ob-
served. After the initial report of a patient with IgAN with five
family members who had hematuria and proteinuria [22], IgAN in
identical twins was subsequently confirmed by kidney biopsy [23].
Since 1978, scattered reports of single families with IgAN [24]
were followed by the study by Julian et al [25] of a pedigree
encompassing seven generations; this included 14 patients with
biopsy-proven IgAN, 17 with clinical hematuria or proteinuria,
and 6 who had died of Bright's disease according to their death
certificate. This pedigree that reaches back nearly 200 years
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strongly suggests a genetic predisposition for at least some
patients with IgAN. The true frequency of familial IgAN remains
uncertain because no serologic marker is yet available and the
diagnosis depends on the histopathology of the kidney. More
recently, Schena, Scivittaro and Raineri studied 269 relatives from
48 families of IgAN patients and found urinary abnormalities in
about 23% of the relatives [26]. In addition, a variety of abnor-
malities of IgA immunobiology were noted in these relatives
including high serum IgA concentration, increased levels of
IgA-IgG complexes, increased serum multimeric IgA and IgA
rheumatoid factor, increased interleukin-2 and interleukin-4, and
increased IgAl production by peripheral blood mononuclear cells
[26]. The significance of these findings will be discussed later.
Further support for the importance of genetically-determined
factors has been sought in studies of HLA antigens. Initially,
IgAN was associated with HLA Bw35 [271; in subsequent studies
from Japan, HLA DR4 was strongly associated [28]. Overall,
reports of associations of HLA antigens or the lack thereof with
IgAN have painted a confusing picture. Unfortunately, most of
these studies have been in relatively small populations; they have
been summarized by Berthoux et al [29]. In a recent study of 196
patients with end-stage renal disease (ESRD) due to IgAN, the
odds ratios for B27 (2.02) and DR1 (1.79) were significantly
increased and for DR2 (0.57) significantly decreased as opposed
to those patients with ESRD due to focal segmental glomerulo-
sclerosis in whom no association with any HLA antigen was found
[30]. The etiology of ESRD in this study was obtained from the
transplant nephrologist and not confirmed by review of biopsy
reports; this is a minor detraction. Rather, the large number of
patients, the comparison with focal glomerulosclerosis, and the
severity of disease lend strength to the findings. Whether a
heterogeneous nature of IgAN or geographic variation accounts
for the differences among studies of HLA associations is prob-
lematic. At present, no positive or negative association of HLA
antigens can be used for diagnostic purposes. The value of these
associations for prognosis in this most recent study requires
confirmation which should be forthcoming from other transplant
populations which uniformly have the necessary HLA typing.
Clinical presentations
Typically, IgAN presents with painless macroscopic hematuria
frequently at the time of infectious illnesses, which are most often
pharyngitis or tonsillitis and less often pneumonia, gastroenteritis,
or urinary tract infection [31]. The course is distinctively different
from that of post-infectious glomerulonephritis in which the onset
of macroscopic hematuria occurs 7 to 14 days after the infection.
The episode is usually brief—about 24 hours—but may last for as
long as a week. About 40 to 50% of patients present with
macroscopic hematuria [12]. It is more common in children and
decreases in frequency with age. Occasionally, flank or abdominal
pain may be associated, and it can be severe. The finding of IgA
vasculitis in the ileum of a patient with apparent IgAN and
abdominal pain forges a clinical link between IgAN and HSP [32].
Microscopic hematuria usually with proteinuria constitutes the
other common initial presentation in another 30 to 40% of
patients. Macroscopic hematuria will occur at sometime in the
course for about 20 to 25% of this subgroup. Obviously, urinary
screening procedures, as are employed in Japan, will markedly
increase the percentage of patients presenting with microscopic
Table 1. Diseases sporadically associated with mesangial IgA
deposition
Connective tissue diseases
Ankylosing spondylitis, rheumatoid arthritis, mixed connective tissue
disease, post-infectious arthritis
Intestinal
Celiac sprue, ulcerative colitis, regional enteritis
Dermatologic
Dermatitis herpetiformis, psoriasis
Neoplastic
Carcinomas (bronchogenic, laryngeal, mucin-secreting), IgA
gammopathy, mycosis fungoides, non-Hodgkins lymphoma
Hematologic
Cyclical neutropenia, mixed ciyoglobulinemia, immune
thrombocytopenia, polycythemia
Miscellaneous
Idiopathic pulmonary hemosiderosis, sarcoidosis, retroperitoneal
fibrosis, amyloidosis, myasthenia gravis, leprosy, HIV infection [38,
39], thin basement membrane nephropathy [148]
hematuria or chance proteinuria as well as the overall prevalence
of IgAN.
Acute renal failure with edema, hypertension, and oliguria
occurs in less than 10% of patients [12]; 20—25% of this subgroup
may require dialysis [31]. A small percentage of these latter
patients have crescentic glomerulonephritis [33, 34]. As with most
forms of glomerulonephritis, hypertension is common. It occurs
infrequently at the time of initial presentation (5 to 10%), but
more commonly as the course of the disease lengthens (30 to
40%) or when IgAN presents beyond the fourth decade of life.
Nephrotic syndrome is an uncommon presentation occurring in
about 5% of all patients, but more frequently in children and
adolescents [13]. It may occur in the setting of diffuse proliferative
glomerulonephritis with or without sclerosis [35, 36]. Alterna-
tively, the IgA deposition may occur with the diffuse epithelial cell
foot process fusion characteristic of minimal change nephropathy.
IgAN has been associated with several diseases [37]. Most of
these associations appear to be random with no hint of pathoge-
netic linkage (Table 1). However, the associations with celiac
sprue (CS) and dermatitis herpetiformis (DH) are rather fre-
quent. CS is caused by the gliadin fraction of gluten. It is
characterized by diarrhea, malabsorption, lymphocytic infiltration
of the lamina propria of the small intestine and circulating
anti-gliadin antibodies; 10% of these patients have DH. On the
other hand, DH is characterized by IgA deposition in the skin and
usually asymptomatic gluten-sensitive enteropathy. CS and DH
are clinically linked and IgA deposits in the mesangium may be
part of their probable common pathogenesis. Alternatively, both
CS and DH could be clinical manifestations of a disorder of IgA
metabolism that more commonly presents as IgAN or HSP.
Although the association with human immunodeficiency virus
(HIV) infection [38, 39] is uncommon, it is of particular interest
because of the presence of circulating idiotypic anti-immunoglob-
ulin antibodies, which are also found in IgAN. Two other diseases
in which mesangial IgA deposition occurs frequently are systemic
lupus erythematosus (SLE) and hepatic cirrhosis; their his-
topathologies will be reviewed later. The clinical presentations
and serology of SLE are sufficiently distinct that they should not
be confused with IgAN or HSP.
Although HSP occurs most commonly in childhood, it has been
reported as well in 70-year-old patients [40]. It is important to
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recognize that, unlike IgAN which can be diagnosed only by
kidney biopsy, HSP can be diagnosed by clinical criteria: abdom-
inal pain, arthritis, and palpable purpura. Although renal mani-
festations are not essential for the diagnosis, one could speculate
that mesangial IgA deposition may be universal in HSP. Where
clinical criteria alone are used as evidence of nephritis in HSP, it
is often assumed that mesangial IgA deposition is present. Thus,
the prevalence of nephritis in HSP varies widely depending on the
criteria used to make the diagnosis of renal involvement.
Diagnosis
Presently the diagnosis of IgAN can be made only by kidney
biopsy. As suggested by the spectrum of clinical presentations, the
light microscopic findings range from minor mesangial changes
through focal and diffuse proliferation to crescentic glomerulone-
phritis [14, 41—43]. Again, this spectrum will be skewed toward
more severe lesions because these are usually associated with a
greater magnitude of proteinuria and lower glomerular filtration
rates (GFR) which, in turn, are likely to prompt the clinician to
perform a kidney biopsy.
The immunohistology is the crux of the diagnosis in which
dominant or codominant mesangial deposition of IgA is the sine
qua non. IgG and 1gM are often present in a similar distribution.
IgA only is present in about 15% of biopsy specimens [9, 14, 22,
44]. Variable degrees of capillary wall staining by IgA are seen in
a small percentage of cases. Immunoglobulin A light chain is
found in excess of the K isotype in the majority of cases of IgAN
unlike in other glomerulonephridities [45]. Immunostaining for
C3 and terminal complement components is nearly universally
present while Clq and C4 depositions are absent or of low
intensity. The histopathology of the kidney is identical in IgAN
and HSP. Further evidence strengthening the linkage between
these two diseases is that antibodies eluted from kidney biopsy
specimens from patients with IgAN or HSP cross react with one
another but not with kidney tissue from patients with other
diseases [46].
In the differential diagnosis of mesangial IgA deposition, the
immunohistology of lupus nephritis characteristically shows IgG,
1gM, and IgA together. Lupus nephritis and not IgAN is likely if
Clq is present at 2+ intensity or greater [44]. These immunohis-
tological findings together with differences in the clinical presen-
tation and serology readily distinguish lupus nephritis from IgAN
or HSP. Hepatic glomerulosclerosis can usually be excluded on
clinical grounds, but the presence of liver disease makes the
diagnosis of IgAN per se more difficult. In this regard, IgA
mesangial deposition is usually absent in patients with hepatic
cirrhosis who have been biopsied for the diagnosis of clinically
evident glomerular disease [471.
Tests of serum and urine are usually directed at two clinical
questions: diagnosis and/or severity of the renal lesion. Unfortu-
nately, in both IgAN and HSP, specific and sensitive tests for these
purposes are not currently available. Serum total igA concentra-
tion (this is what is routinely measured when serum IgA is
requested from the clinical laboratory) is elevated in 33 to 50% of
adults with IgAN and in a somewhat higher percentage in children
[48]. Serial determinations have not been made or correlated with
any measure of the severity or activity of the disease in any sizable
population. Thus, this test is not worthwhile for either making the
diagnosis or following the course of the disease. High concentra-
tions of A light chain are a distinctive feature of serum IgA in
IgAN unlike the predominance of the K isotype in normal serum
[49]. The significance of this finding for pathogenesis is unknown.
Urinary immunoglobulins are not distinctive in IgAN [50].
Although the presence of alternative complement pathway
proteins in the glomerulus suggests activation of complement in
the pathogenesis [42, 51], serum complement components and
control proteins are normal in IgAN [52]. Nevertheless, several
deficiencies of complement proteins have been associated with
both IgAN and HSP [53]. These include complete C3 deficiency,
partial H, P, I, C2, and C4BP deficiencies, and C4 isotype
deficiency. The C3F and the BfF phenotypes also have been
associated in two studies. While determinations of complement
profiles may provide useful linkage information in familial IgAN,
they do not help with either diagnosis or assessment of activity.
Determination of IgA-fibronectin aggregates initially showed
promise of providing the clinician with a serologic test to diagnose
IgAN [54, 55]. Unfortunately, further study has shown that, while
strongly positive levels of these aggregates may help to differen-
tiate IgAN from other forms of glomerulopathy, this test is not
diagnostic [56]. In that study, only 25 of 52 patients had an
elevated level of these aggregates on at least one occasion during
the course of their disease. The sensitivity of the test is not
sufficient to make the diagnosis, and the level does not correlate
with the activity or severity of the glomerular lesion. Furthermore,
the specificity of the test has recently been challenged [57].
Indeed, the binding of fibronectin may be a normal process
enhanced by circulating IgA immune complexes [58, 59].
Anti-neutrophil cytoplasmic antibodies (ANCA) are distinctly
uncommon in IgAN and HSP. A recent cross sectional and
longitudinal study [60] showed IgG ANCA in only 2 of 100
patients with IgAN and in none of 30 patients with HSP; none of
the 50 patients followed serially developed ANCA. No IgA
ANCA was detected.
As will be discussed later, immunoregulation appears to be
defective in IgAN. Most of the serum assays that provide evidence
for such defect(s) are not routinely available and have been
carried out mainly in the course of clinical research. However,
levels of serum IgA rheumatoid factor (RF), which is an IgA
antibody against the Fe portion of IgG, are increased in both
IgAN and HSP [61—63]. Eight of 25 patients (32%) had elevated
serum IgA RF levels; only one of these eight had a elevated 1gM
RF [62]. In addition, 13 of 24 children with HSP (54%) had
elevated IgA RF, but none had elevated 1gM or IgG RF [63].
Although these assays are not widely available and have low
sensitivity for IgAN and HSP, contemporaneous determinations
of IgA, IgG, and 1gM RF have the potential of providing a
serologic diagnosis of IgAN or HSP if a kidney biopsy was deemed
inadvisable. Clearly, these tests would have to be applied in much
larger numbers of patients before one could be confident of the
specificity for IgAN. The presence of IgA RF in serum provides
yet another link between IgAN and HSP.
Deposits of IgA in the blood vessels of the skin have been
shown in IgAN and HSP [64]. However, IgA deposits do not occur
with sufficient frequency in IgAN to recommend skin biopsy for
diagnosis and occur frequently in other renal diseases [65]. Thus,
both the sensitivity and specificity of this test is low.
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Pathophysiology
An understanding of sequential events in the pathogenesis is
the key to the development of successful therapy. Despite inten-
sive investigation by several groups, a widely accepted hypothesis
for the pathogenesis of IgAN has not yet emerged but several
theories have their proponents. These theories have focused on at
least four possibilities: (1) the ability of a certain antigen(s) to
cross the mucosa or (2) a more generalized defect at the mucosal
barrier per Se; (3) an intrinsic defect in the structure of IgA; or (4)
a defect in immune regulation, which includes the possibility of
autoimmunity. Although the single diagnostic criterion of me-
sangial IgA deposition promotes a monolithic view of IgAN, this
criterion may actually define a group of diseases. If that is the
case, several different pathogenetic mechanisms may apply. How-
ever, at present only IgAN and HSP are clinically recognized
entities. Since these two disorders share many of the same disease
manifestations, it seems likely that they have the same pathogen-
esis. The following discussion will take this tack with notations of
features common to both.
Animal models provide opportunities not available in patients
to dissect pathogenesis. Early animal models of IgAN, which were
produced by immunization with enteral or parenteral antigen [66]
or by injection of preformed immune complexes [67], showed
mesangial deposition of IgA and J chain indicative of multimers of
immunoglobulins and the absence of secretory component. Un-
like human disease, no third component of complement (C3) was
present and no hematuria or proteinuria was shown. While these
models provided insights into the nature of IgA deposited in the
mesangium, they do not result in a kidney disease that reflects the
human condition or produce the abnormal antibodies observed in
patients with IgAN. More recent models including the ddY mouse
[68] and the anti-Thy-i rat [69] may relate more closely to human
IgAN, but at this point the data are not yet sufficiently advanced
to incorporate observations from these models into a review of the
human disease.
The observations that pharyngitis, bronchitis, or gastroenteritis
commonly precipitate an episode of hematuria in IgAN and the
frequent association of IgAN with inflammatory bowel diseases
(Table 1) suggest the first two of the above-mentioned pathoge-
netic possibilities [70]. An examination of the different character-
istics of the products of the systemic and mucosal IgA systems
provide some insight into these possibilities.
If the mucosa-associated system were the source of the in-
creased macromolecular IgA in the circulation in IgAN, one
would expect altered IgA production by that system in terms of
the amount, size, or subclass, including some increase in serum
IgA2 levels. Circulating IgA has been shown to contain increased
levels of both total IgAl and IgAl-containing immune complexes
in patients with IgAN [62, 71, 72]. In bone marrow, IgAl-
producing plasma cells are increased and produce predominantly
multimers [73]. In contrast, both IgA1 and IgA2 production in
saliva, a secretion of the mucosal system, does not differ in
patients with IgAN compared to controls [74]. However, the same
group of investigators showed that after immunization with teta-
nus toxoid, salivary IgA production increased in patients with
IgAN but not in controls, suggesting that the mucosal system is
abnormal in IgAN. However, serum IgAl and IgA2 antibodies
increased similarly in both groups [75]. Unfortunately, antibody
size may not be a good differentiating feature for the system of
origin because serum IgA antibodies specific to the immunogen
are predominantly multimeric early in the immune response
whether the route of immunization is enteral or parenteral [76].
Although these data are not in complete accord, on balance they
favor a systemic origin for circulating multimeric IgA.
Specific exogenous antigens have been implicated by some
studies. Oral ovalbumin loading in patients with IgAN shows some
increase in specific multimeric IgA antibodies to this protein [77].
Conversely, antigen exclusion by a gluten-free diet decreases
anti-gliadin IgA antibodies, IgA immune complexes, and protein-
uria [78] in patients with IgAN. Increased serum levels of antibody
against several microbes including pneumococcal polysaccharides,
herpes simplex virus, cytomegalovirus, Epstein-Barr virus, and E.
coli have also been reported. Some of these specific antibodies
have also been detected in glomerular deposits [70]. The serum
antibodies to a variety of common environmental antigens—both
dietary and microbial—are almost exclusively multimeric IgAl.
While these IgAl antibodies are present in significant titers in
serum, median values did not differ between normal humans and
those with IgAN or HSP [79]. In addition, IgA2 antibodies were
present in low titers and again did not differ between patients with
IgAN and normal subjects [79]. The characteristics of serum IgA
in these studies resemble those of IgA originating in the bone
marrow-associated compartment more than those of the mucosa-
associated compartment. Thus, the data suggest that the forma-
tion of IgA antibodies directed at a wide spectrum of environ-
mental antigens is a normal event. In fact, increased serum IgA1
antibodies to several environmental antigens have been detected
also in membranous nephropathy, minimal change disease, and
membranoproliferative glomerulonephritis [80]. This reinforces
the notion that IgA produced by the mucosa-associated system
does not play a key role in the pathogenesis of IgAN. These data
do not exclude a defect in the mucosal barrier in CS. However, if
this were the case in IgAN and the antigens that gained access to
the systemic IgA compartment evoked an abnormal antibody
response, increased levels or abnormal forms of serum antibodies
to environmental antigens would be expected in patients with
IgAN. The data do not support such a mechanism.
The immunopathology of IgAN also provides important clues
regarding pathogenesis. IgA may deposit in the mesangium
because: (1) one or more of its physicochemical properties cause
it to be trapped there; (2) it binds to a deposited antigen(s); or (3)
it binds to an intrinsic mesangial antigen. Initial studies of IgA
subclasses reported the deposition of both IgA1 and IgA2 in
IgA-associated nephropathies [81] leading those authors to pos-
tulate that the mucosa played a pivotal pathogenetic role. How-
ever, Conley, Cooper and Michael [82] showed by using more
specific reagents that IgA1 subclass selectively was deposited in
the mesangium in IgAN, HSP and SLE. This nearly exclusive
deposition of IgAi has been confirmed by several investigators
[79, 83—85], and is more consistent with IgA originating in the
systemic and not the mucosal system. In hepatic cirrhosis, IgA
deposits, if they occur, are usually IgAl and IgA2, unlike those in
IgAN or HSP. This suggests a different pathogenesis in hepatic
glomeruloscierosis probably involving impaired biliary excretion
of IgA multimers.
Other structural characteristics have been examined to deter-
mine the nature and origin of deposited IgA. The multimeric
nature of deposited IgA antibodies has been suggested by the
presence of J-chain in several studies [86—88]. However, because
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1gM also contains J-chain, codeposits of 1gM must be carefully
excluded to conclude that multimeric IgA is present. Secretory
component was seen commonly in hepatic glomerulosclerosis and
SLE but rarely in IgAN and HSP [841. Others have not observed
secretory component in any IgA-associated glomerular disease
[85]. Finally, IgA actually eluted from the kidneys of patients with
IgAN has been characterized as multimeric with an anionic charge
(p1 = 4.5 to 6.8) [89]. Thus, these data suggest that deposited IgA
is multimeric but they do not conclusively establish the IgA system
of origin.
Antibodies to several viruses including herpes simplex, hepatitis
B, adenovirus, and cytomegalovirus and to several foods including
soy, bovine milk and rice proteins have been detected in the
mesangium of patients with IgAN usually but not always coinci-
dent with IgAl deposits [90]. Where tested, these antibodies are
of the IgAl subclass [79]. These studies must be interpreted with
caution because the reactivity of some antisera, particularly
polyclonal antibodies, may be non-specific with human tissue or
other unrelated antigens. Nevertheless, the data show that no
specific or characteristic microbial or food antigen has been
identified in the glomeruli of patients with IgAN. Since similar
circulating antibodies specific to environmental antigens are
present in normal subjects as well as in patients with IgAN, it
seems likely that the array of deposited antibodies has little or
nothing to do with the nature of the particular antigens.
The physical and immunological characteristics of circulating,
secreted, and deposited IgA join with several other lines of
evidence to suggest that disordered immune regulation or pro-
duction underlies the pathogenesis of IgAN and HSP. Among the
IgAl-containing immune complexes, multimeric IgAl RF has
been shown in both IgAN and HSP. Increased IgG antibodies and
decreased 1gM antibodies against the Fab fragment of the a heavy
chain have also been demonstrated in these patients [91]. Al-
though a similar pattern of antibodies against immunoglobulins
are also seen in patients infected with HIV [92], IgA deposition in
the kidney is distinctly uncommon in HIV-infected patients [93],
notwithstanding recent reports [38, 39]. This suggests that the
mere presence of these circulating autoantibodies alone does not
account for mesangial IgA deposition.
Further support for a more generalized disorder of immune
regulation is the finding of two IgG antibodies to autoantigens
present in the mesangium [94]. These antibodies were detected in
sera of patients with both IgAN and HSP and the titer correlated
with hematuria and proteinuria. Circulating anti-endothelial cell
antibodies have been detected in IgAN, but are found in lupus
nephritis and systemic vasculitis as well [95]. These data extend
the spectrum of antibodies formed in IgAN to both fixed and
circulating endogenous antigens.
The role of the complement in the pathogenesis is problematic.
IgA is not a predictable or potent activator of complement but
alternative pathway components nearly always accompany IgA
deposits [96]. Although IgA immune complexes can activate the
alternative pathway, they bind complement and C3b poorly. Since
C3b is the natural ligand for the complement receptor, CR1, on
human erythrocytes, IgA immune complexes may be more patho-
genic for the kidney because of greater difficulty in safely clearing
them from the circulation [97]. It has been postulated that
IgG-IgA complexes are necessary for complement activation
which may occur locally in the kidney and account for the
presence of the membrane attack complex in the mesangium.
However, mesangial C3 is present even in the absence of IgG or
1gM deposits. Whether the amount of mesangial deposition of
IgG or 1gM might fluctuate during the course of disease to
account for their absence in some instances is not known.
Abnormalities in the activity of the cellular immune system
have been detected in IgAN and HSP. Studies of T lymphocytes
suggest that increased T helper (CD4) lymphocytes and decreased
T suppressor (CD8) lymphocytes occur with exacerbation of
disease [98]. Specifically, Ta4 cells with the capacity to switch
from 1gM to IgA synthesis are increased in IgAN [99]. In response
to tetanus toxoid, patients with IgAN more commonly had
undetectable amounts of an IgG subclass (IgGi and/or IgG4, and
less commonly IgG3) while IgA concentrations rose [100]. These
authors suggested that IgG to IgA switching was impaired in
IgAN. In further support of a role for Ta4 cells, restriction
fragment length polymorphism analysis in patients with IgAN has
shown an increased frequency of the Sal allele, that portion of the
gene that mediates the switch from 1gM to IgA [101]. Transform-
ing growth factor /3, which induces the IgA isotype switch, and
IL-5, which promotes differentiation in IgA-bearing B lympho-
cytes, may also be elevated in patients with IgAN [45]. Finally,
increased production of IL-4, which may mediate the switch to
IgA production, has been observed in patients with IgAN and
their relatives [26].
Whether the number of circulating IgA-bearing B lymphocytes
is abnormal in IgAN is controversial. The inconsistent results
among several studies may relate to admixed T and B lymphocytes
in the peripheral blood sample or may be dependent upon the
activity of the disease at the time of sampling [102]. The use of
mitogen stimulation also confounds the interpretation of some
studies—not all cited here [45]. Nevertheless, a preponderance of
in vitro studies shows increased production of IgA, IgG and/or
1gM by B lymphocytes—even when clearly isolated from T
lymphocytes—in patients with IgAN and HSP and their relatives
[103—106]. Taken together, the data suggest that both T and B
lymphocytes are engaged in supporting increased IgA production.
However, excess production alone is an unlikely sole cause of
mesangial IgA since IgA myeloma rarely results in tissue deposi-
tion. Thus, a structural—immunological or physicochemical—
abnormality in the IgA produced by patients with IgAN has been
sought as a possible cause of mesangial IgA deposition.
Polyclonal idiotypic antibodies directed against bovine serum
albumin (BSA) have been shown in the sera and mesangiums of
patients with IgAN, the titer of which correlated with hematuria
[107]; a defect in anti-idiotype production was not shown. The fact
that the idiotype was derived from serum IgG antibodies prese-
lected for activity against BSA makes the significance of this
observation uncertain [108]. To search for idiotypic antibodies
that are pathogenic in IgAN, van den Wall Bake and coworkers
took advantage of an opportunity to elute IgA from the renal
cortex and isolated glomeruli of a kidney obtained from a patient
with IgAN. Monoclonal anti-idiotypic antibodies specifically di-
rected against those eluted antibodies were then developed [109].
Only five different monoclonal antibodies were raised; all reacted
specifically against VK3a light chain and not toward any heavy
chain. These antibodies reacted against pooled serum and plasma
cells of patients with IgAN and normal subjects. In addition, they
reacted against 26 of 31 kidney biopsies of patients with IgAM, 6
of 6 with HSP and virtually all kidney biopsies from patients with
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lupus nephritis, membranous glomerulopathy, membranoprolif-
erative glomerulonephritis, and essential mixed cryoglobulinemia.
Thus, the only idiotype expressed in deposited IgA antibodies is
shared not only by patients with IgAN but also a broad spectrum
of glomerulopathies. This lack of specificity for IgAN may be due
to a failure to identify a particular antigen in this case. Alterna-
tively, it suggests that mesangial IgA is highly polyclonal. If the
latter possibility is correct, the data would be consistent with the
hypothesis that deposition is linked to some abnormal property of
the polyclonal IgA antibody in IgAN.
Abnormalities in the structure of IgA in IgAN have not been
intensively investigated thus far. Human IgAl contains an unusual
0-galactosylation hinge region on the heavy chain, a process that
is under the control of the enzyme, f31,3-galactosyltransferase
(/31,3-GT). The asialoglycoprotein receptor (ASGP-R) in the
liver, which is the major site for the catabolism of IgA [1101, has
been shown to be specific for these terminal galactose residues. It
is possible that decreased galactosylation or inaccessible galactose
residues may alter the clearance of IgAl or IgAl-containing
immune complexes leading to mesangial deposition. In this re-
gard, Mestecky et a! showed that IgAl in patients with IgAN is
deficient in galactose residues [1111. They hypothesized that a
deficiency of f31,3-GT may be an important primary cause of IgA
deposition. A linkage between this structural abnormality and the
evidence for polyclonal B lymphocyte activation will have to be
incorporated into a coherent hypothesis. Conceivably, a structur-
ally abnormal antibody is somehow not recognized in the feed-
back mechanism of antibody production thereby resulting in
augmentated production. There is no evidence that elevated
anti-a-galactosyl IgG antibodies in patients with IgAN and HSP
during episodes of hematuria [112] is linked to defective galacto-
sylation. These antibodies may be simply one of many circulating
antibodies in IgAN.
Infrequently, serial kidney biopsies in patients with hematuria
and proteinuria have uncovered patients with IgAN who did not
show mesangial IgA deposition at the outset of their renal disease
[113]. These cases challenge the notion that the IgA deposits lead
to hematuria and proteinuria and the pathogenetic significance of
these deposits. Early antigen deposition with or without cell-
mediated immune responses, the rate of IgA immune complex
formation and more effective clearance by mesangial cells that
possess IgA Fc receptors or clearance by neutrophils which also
have IgA Fc receptors are among the mechanisms speculated to
explain these observations, which will have to be incorporated into
any hypothesis regarding pathogenesis.
Although considerable data have been amassed on the role of
cytokines, autocoids and growth factors in the pathogenesis of
mesangial proliferation and sclerosis, their actions have not been
shown to apply exclusively or largely to IgAN or HSP. These data
will not be considered here even though therapeutic regimens of
the near future may be directed at these pathways.
Prognosis
Chronic renal failure and ESRD is the eventual outcome in 30
to 35% of patients with IgAN. For example, of the 119 patients
originally diagnosed at the Necker Hospital prior to 1973, 74 have
had regular follow-up there. Of these, 22 are in clinical remission,
28 have chronic renal failure, and the remainder have persistent
proteinuria or hematuria [114]. Life-table analysis of several series
from Asia, Australia, Europe and North America shows a 10-year
renal survival of 80 to 90% [115].
From the clinical standpoint, the important risk factors at the
time of diagnosis for subsequent severe renal failure are renal
insufficiency and proteinuria (>1.5 g/24 hr). Many investigators
find that hypertension or the absence of macroscopic hematuria
also predicts a poor outcome [115].
From the histopathologic perspective, glomerular sclerosis,
interstitial fibrosis, and involvement of the glomerular capillary
wall all bode a poor outcome [115]. Histologic remission of IgA
deposits is uncommon [113].
Other factors have been associated with a poor outcome: IgAN
is more severe in patients with C4A deficiency [116]. Increased
frequency of HLA B-35 [117], B27, and DR1 [30] has been
detected in patients with ESRD due to IgAN.
Treatment
Therapeutic trials that convincingly show a long-term beneficial
effect on the progression of renal insufficiency in IgAN and HSP
are wanting [118, 119]. Such trials are difficult to carry out because
IgAN progresses toward renal failure slowly over several years in
a minority of patients. No cure is known at present.
As with many glomerulopathies, corticosteroids with or without
immunosuppresive agents have been used in several studies
usually confined to patients considered to be at risk for progres-
sive renal failure. Short-term trials in patients with heavy protein-
uria have shown inconsistent results: Although Lai et al [120]
found no benefit over four months, Kobayashi and coworkers
observed stable renal function in patients with initial creatinine
clearances greater than 70 mI/mm treated with daily prednisone
for over 18 months compared to those who received non-steroidal
anti-inflammatory agents or anticoagulants [121]. More recently, a
beneficial effect of alternate-day steroid therapy has been shown
in a small uncontrolled trial over 54 months in six children with
IgAN associated with more than 1 glday of proteinuria or
glomerular or interstitial sclerosis on kidney biopsy [122]. Based
on these encouraging findings, Julian et al have been conducting
a multicenter prospective trial of alternate-day prednisone com-
pared to no treatment in patients with IgAN who are at risk by
virtue of severe proteinuria (greater than 2 g/day) or biopsy
evidence of chronicity [123, 124]. Prednisone was given thrice
weekly, started at 60 mg/day, and tapered slowly to 10 mg/day by
protocol over 24 months. The alternate-day regimen was used to
minimize the often serious side effects of corticosteroid therapy.
Only 11 patients have completed the protocol thus far [124] and
no further deterioration in GFR has been detected in either
group. Glucose intolerance developed in 2 of 17 treated patients.
At this juncture, prednisone does not appear to offer a beneficial
effect other than modest amelioration of proteinuria. Because of
the indolent course, more patients and/or longer periods of
observation will be necessary to reach a conclusion. A meta-
analysis of randomized controlled trials of corticosteroids and/or
cytotoxic agents supports the conclusion that corticosteroids
reduce severe proteinuria (greater than 3 g/day) in patients with
IgAN [125].
The exception to this uncertain effect of corticosteroids is found
in children with IgA deposition in the setting of minimal change
nephrotic syndrome, which shows classical diffuse epithelial cell
foot process fusion. Such patients respond to corticosteroid
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therapy with prompt resolution of proteinuria in keeping with the
experience with typical minimal change disease [126, 1271.
Combination therapy with cyclophosphamide, dipyridamole
and warfarin has been used in two long-term trials. The primary
benefit in both trials was a reduction in the magnitude of the
proteinuria; no conclusive effect on GFR was observed [128—130].
Cyclosporin for 12 weeks decreased proteinuria but also creati-
nine clearance in treated patients [131]; no further studies on this
agent have been reported.
Several other treatment regimens including phenytoin, anti-
platelet drugs, eicosopentaenoic acid, urokinase, dapsone, sodium
cromoglycate, dietary gluten restriction and plasma exchange
have been tabulated and summarized by Clarkson et al [119].
With the exception of urokinase, none of these has been shown to
be beneficial to preserve GFR. Urokinase therapy was compared
to a variety of anti-platelet drugs in the control group without
randomization. The rationale for this therapy was based on the
finding of fibrinogen in the glomeruli of patients with IgAN [132].
Although it was concluded that urokinase improved GFR, this
conclusion was based on a marked rate of rise of serum creatinine
concentration in one patient in the control group who had
proteinuria of more than 1 glday. Urokinase cannot be recom-
mended based on this study, regardless of the statistical conclu-
sion.
The tonsils as a part of the systemic IgA system contribute
predominantly IgAl and may act as activators or effectors of IgA
dysregulation in IgAN [133]. Tonsillectomy, which has not been
vigorously pursued for its potential benefit, has recently been
shown to be associated with a decrease in proteinuria (from 3.5 to
0.9 g/day after 4 years), hematuria and serum total IgA concen-
tration in 34 patients with IgAN and recurrent infections.
Whether all 34 patients were followed for at least four years is not
stated [133]. The serum creatinine concentrations recorded in this
report are difficult to interpret but did not appear to rise over the
four years of follow-up. Since this magnitude of proteinuria is a
poor prognostic sign (most all studies concur on this point),
tonsillectomy clearly benefited these patients and did not ad-
versely affect GFR. Thus, tonsillectomy appears to be indicated in
patients with recurrent infection; whether other patients with
IgAN would benefit is a question of some import that merits
further careful study.
Deficiencies of essential fatty acids have been detected in
patients with IgAN [134]. These patients, all 15 of whom were at
increased risk for progressive renal failure by virtue of decreased
GFR, heavy proteinuria or hypertension, were treated with fish oil
supplements for one year at which time a significant decrease in
proteinuria and increase in GFR were observed. Whether this
beneficial effect of fish oil is on glomerulonephritis in general or
is related specifically to IgAN cannot be determined from this
study. A larger randomized clinical trial has been completed (Note
added in proof).
Abnormalities of generalized immunoglobulin production—
confined to not only IgA—have been recognized [92, 135]. Based
on these data and the finding of a deficiency of mainly IgGi
subclass in patients with IgAN and HSP, a recent trial of
high-dose immunoglobulin therapy proved successful in 11 pa-
tients with severe IgAN or HSP [136]. When intravenous followed
by intramuscular immunoglobulins were administered over nine
months, the decline of nearly 4.0 ml/min/month in GFR was
nearly completely arrested along with a decline in hematuria and
proteinuria over a median 14 month follow-up. Relapse appeared
to be prompt if therapy was discontinued. Thus, administration of
pooled human immunoglobulins appears to arrest the disease.
Prospective, controlled trials are in order probably limited to
patients at high risk for progression.
Hypertension and heavy proteinuria both are associated with a
poor prognosis in virtually every study of the natural history of
IgAN and HSP. Converting enzyme inhibitors (CEI) have proven
superior to other antihypertensive agents in delaying the progres-
sion of renal failure and diminishing proteinuria. This has been
shown for 22 patients followed for 20 months treated with CE!
compared to 34 patients treated with 13-adrenergic antagonists
followed for more than 36 months [137]. In addition, a retrospec-
tive analysis of 115 patients with !gAN and more than 1 g/day of
proteinuria showed that those who were hypertensive and treated
with a converting enzyme inhibitor (CE!) had a slower rate of
progression of renal insufficiency [creatinine clearance: (—)0.4vs
(—) 1.0 ml/minlmonth] and a higher frequency of remission of
proteinuria (18.5 vs. 1.8%) than those treated with other antihy-
pertensive medications [138]. Therefore, treatment of hyperten-
sion in severe IgAN with CE! is superior to other antihypertensive
regimens. Whether treatment with CEI is useful in normotensive
proteinuric patients with IgAN is not known.
While some have lamented that we have not progressed beyond
corticosteroid therapy in 25 years of study, others see brighter
prospects for the treatment of glomerular disease [139, 140].
Several of the aforementioned treatments for patients at risk are
new and must await support by further study before an unqualified
endorsement is in order. Given that proviso, if a patient has
rapidly deteriorating renal function (GFR > —2 mI/mm/month),
immunoglobulin therapy should be considered; hypertension
should be treated with a CE! preferably; and, if only proteinuria
(>1 g/day) is present, a course of alternate day corticosteroids
may prove beneficial. As the new avenues of investigation in IgAN
define specific steps in its pathogenesis, modern molecular bio-
logical agents can and are being developed. With new monoclonal
agents capable of blocking the action of specific cytokines and
growth factors, it may become possible to arrest or retard the
progression of mesangial proliferation and sclerosis in IgAN and
HSP as well as other forms of glomerulonephritis. However, as
Couser has observed, we must overcome the organizational
barriers for the prompt and effective assessment of such new
agents for these diseases that are of relatively low incidence in the
general population. He has called for the development of a single
data bank—a national registry—for glomerulonephritis to provide
the necessary pool from which studies with sufficient numbers of
patients enrolled can obtain prompt answers [140]. Clearly, with
the widespread availability of facsimile machines and computers,
the involvement of the private nephrologist along with the acade-
mician with a minimum of effort is entirely feasible. Except for
isolated efforts, the nephrology and nephropathology community
in the United States is well behind our colleagues in other
disciplines and countries in this regard. Now is the time to correct
the problem.
Kidney transplantation in !gAN is effective and has also pro-
vided insights into some of its fundamental pathogenetic aspects.
Mesangial IgA deposition has been shown to occur soon after
transplantation [141, 142]. A patient with ESRD due to HSP also
has developed mesangial IgA deposition in the renal allograft with
no systemic manifestations [143], further linking HSP with IgAN.
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On the other hand, when a kidney from a donor with subclinical
IgAN was inadvertently transplanted into a recipient with ESRD
due to a disease other than IgAN or HSP, mesangial IgA
deposition promptly resolved [144]. These two observations
strongly support the systemic nature of IgAN. The recurrence of
mesangial IgA is not necessarily associated with recurrent pro-
gressive renal insufficiency. However, after several years renal
failure due to IgA disease alone may ensue despite maintenance
immunosuppressive drugs including cyclosporin [1451.
Of all the common diseases that lead to ESRD, the cadaveric
kidney allograft survival is highest in IgAN at both one-year
(87%) and three-years (77%) [146]. Furthermore, Lim et al have
recently observed that patients with IgAN who had IgA antibodies
to HLA antigens had a 100% two-year kidney allograft survival
compared to a 70% survival rate in IgAN patients who did not
have antibodies against HLA [147]. They hypothesized that these
autoantibodies to HLA antigens block IgG antibodies or inhibit
cellular immune responses to enhance graft survival. Whatever
the explanation, early kidney allograft survival is excellent in
IgAN.
Summary
IgAN is the most common type of glomerulonephritis world-
wide, and is found more in men and distinctly less in blacks. It
presents with macroscopic hematuria in about 40 to 45% of
patients, with microscopic hematuria and proteinuria in about 35
to 40%, and with nephrotic syndrome or acute renal failure in the
remainder. The diagnosis continues to rely on the finding of the
dominant or codominant mesangial deposition of IgA on immu-
nohistologic examination of the kidney. No blood or urine test is
sufficiently reliable for diagnosis. While the pathogenesis remains
unknown, accumulating evidence suggests that polyclonal stimu-
lation of immunoglobulins perhaps coupled with structural abnor-
malities of IgA play pivotal roles. These defects may account for
the variety of autoantibodies detected in patients with both IgAN
and HSP. While IgAN has an indolent course, about 30% of
patients will reach ESRD after 20 years, particularly in those who
present with hypertension, heavy proteinuria or renal insuffi-
ciency. At present, therapy is disappointing, but immunoglobulin
supplementation and newer agents that interrupt the pathways of
mesangial proliferation and sclerosis hold promise for the future.
Kidney transplantation has shown excellent allograft survival.
JOHN H. GALLA
Cincinnati Ohio, USA
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Note added in proof
A placebo-controlled, randomized trial has recently shown a decrease in
the rate of rise in serum creatinine and in ESRD. DONADIO JV JR.
BERGSTROM EJ, OFFORD KP, SPENCER DC, HOLLEY KE, for the Mayo
Nephrology Collaborative Group: A controlled trial of fish oil in IgA
nephropathy. NEnglJMed 331:1194—1199, 1994
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